NRx Pharmaceuticals has received FDA approval for its preservative-free injectable ketamine, clearing a major regulatory hurdle for a product the company says it has already manufactured in the United States. The approval comes ahead of the FDA’s November 10 target date and gives NRx a potential commercial entry into a market where ketamine injections have faced ongoing supply shortages.
The product is made with Nephron Pharmaceuticals in South Carolina using blow-fill-seal technology. NRx says it is intended for hospitals and clinics, where injectable ketamine is used mainly for anesthesia and pain control.
Key details
-
FDA approval: The agency approved NRx’s application for its preservative-free ketamine injection on October 30. NRx said the approval arrived ahead of the FDA’s November 10 goal date.
-
Formulation: The product does not contain benzethonium chloride, or BZT, an antimicrobial preservative that NRx says is present in currently available ketamine injections. The company says the formulation avoids potential risks associated with BZT.
-
U.S. manufacturing: NRx is working with Nephron Pharmaceuticals to produce the drug in West Columbia, South Carolina, using blow-fill-seal manufacturing technology. The company presents the product as an effort to bring sterile injectable drug production back to the United States.
-
Supply opportunity: NRx’s CEO said ketamine injection has been in short supply since 2018, remains on the FDA’s drug-shortage list, and has seen some manufacturers discontinue production. He said commercial supply is on hand and that the approval allows the company to label the product and supply hospitals and clinics.
-
Clinical use cited by the company: NRx said injectable ketamine is used primarily for anesthesia and pain control, including in labor and delivery. The announcement did not describe the product as a treatment for depression, PTSD or suicidality, despite those areas being part of NRx’s broader business focus.
What changes for investors
The approval moves NRx’s ketamine product from regulatory review toward commercialization. The company says it has supply available, but the announcement did not provide a launch date, pricing, sales targets or expected revenue. The commercial scale and financial contribution of the product therefore remain unspecified.